Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2009-08-31
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Bedrest will blunt the anabolic response to a mixed nutrient meal, facilitating a loss of muscle mass and functional capacity that is only partially restored during rehabilitation.
2. Enriching daily meals with leucine will promote protein synthesis and maintain the anabolic response to mixed nutrient meal ingestion. This will preserve lean muscle mass and function during bedrest and facilitate the recovery of functional and metabolic capacity during rehabilitation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Effects of Nutritional and Exercise Countermeasures
NCT00447044
Optimization of the Preservation of Muscle Mass and / or Its Recovery by a Protein-energy Chrononutrition Approach Dissociated From Meals
NCT03867006
Preserving Muscle Mass and Function in Bedridden Older Adults
NCT01846130
Can Supplemental Leucine Offset Disuse-induced Muscle Atrophy?
NCT03762278
The Effect of Nandrolone Decanoate and Leucine on Muscle Loss
NCT02376309
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We will employ our established 14 day bed rest protocol to model the skeletal muscle unloading that occurs during microgravity. We will also examine recovery of muscle mass and functional capacity during a 7 day rehabilitation period. We will study 2 groups: CON (Bedrest/Recovery + Placebo; n=15), LEU (Bedrest/Recovery + Leucine; n=15). We will assess a) markers of translation initiation, b) muscle protein synthesis, c) muscle mass and body composition and d) strength and aerobic capacity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Leucine
3-4 g Leucine added to daily meals during bed rest
Leucine
3-4g Leucine added to daily meals
Placebo
3-4 g Alanine added to daily meals during bed rest
Alanine
Powered amino acid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Leucine
3-4g Leucine added to daily meals
Alanine
Powered amino acid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Ability to sign informed consent
Exclusion Criteria
2. Subjects with uncontrolled metabolic disease
3. A GFR \<65 mL/min/1.73m2 or evidence of kidney disease or failure
4. Subjects with vascular disease or risk factors of peripheral atherosclerosis
5. Any history of hypo- or hyper-coagulation disorders. (e.g., Coumadin use or history of DVT or PE)
6. Subjects with chronically elevated systolic pressure \>150 or a diastolic blood pressure \> 100
7. Subjects with implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)
8. Subjects with recently (6 months) treated cancer other than basal cell carcinoma
9. Any subject currently on a weight-loss diet or a body mass index \> 30 kg/m2
10. Inability to abstain from smoking for duration of study
11. A history of \> 20 pack per year smoking
12. Any subject that is HIV-seropositive or has active hepatitis
13. Recent anabolic or corticosteroids use (within 3 months)
14. Subjects with hemoglobin or hematocrit lower than accepted lab values
15. Agitation/aggression disorder
16. History of stroke with motor disability
17. A recent history (\<12 months) of GI bleed
18. Any other condition or event considered exclusionary by the PI and faculty physician
45 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Space Biomedical Research Institute
OTHER
The University of Texas Medical Branch, Galveston
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Douglas Paddon-Jones, PhD
Role: PRINCIPAL_INVESTIGATOR
The University of Texas Medical Branch at Galveston
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Texas Medical Branch
Galveston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
English KL, Mettler JA, Ellison JB, Mamerow MM, Arentson-Lantz E, Pattarini JM, Ploutz-Snyder R, Sheffield-Moore M, Paddon-Jones D. Leucine partially protects muscle mass and function during bed rest in middle-aged adults. Am J Clin Nutr. 2016 Feb;103(2):465-73. doi: 10.3945/ajcn.115.112359. Epub 2015 Dec 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MA02001
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
09-121
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.